Liberum Capital reiterated their hold rating on shares of AstraZeneca (LON:AZN) in a research note published on Friday, September 20th, ThisIsMoney.Co.Uk reports.
Several other brokerages also recently weighed in on AZN. JPMorgan Chase & Co. reiterated an overweight rating and issued a GBX 7,900 ($103.23) price target on shares of AstraZeneca in a report on Monday, September 16th. Jefferies Financial Group reiterated a neutral rating on shares of AstraZeneca in a report on Thursday, August 29th. Goldman Sachs Group set a GBX 5,500 ($71.87) price target on AstraZeneca and gave the stock a sell rating in a report on Monday, September 2nd. Citigroup reissued a buy rating and issued a £100 ($130.67) price objective (up previously from GBX 7,000 ($91.47)) on shares of AstraZeneca in a research note on Wednesday, September 11th. Finally, Deutsche Bank increased their price objective on AstraZeneca from GBX 7,600 ($99.31) to GBX 7,800 ($101.92) and gave the stock a buy rating in a research note on Monday, September 9th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of GBX 7,050 ($92.12).
Shares of AZN stock opened at GBX 7,383 ($96.47) on Friday. The company has a debt-to-equity ratio of 144.48, a current ratio of 0.95 and a quick ratio of 0.74. The stock’s 50 day simple moving average is GBX 7,215.79 and its two-hundred day simple moving average is GBX 6,452.32. AstraZeneca has a 1 year low of GBX 5,312 ($69.41) and a 1 year high of GBX 7,583 ($99.09). The company has a market cap of $96.86 billion and a PE ratio of 43.13.
The firm also recently disclosed a dividend, which was paid on Monday, September 9th. Stockholders of record on Thursday, August 8th were given a GBX 71.90 ($0.94) dividend. The ex-dividend date was Thursday, August 8th. This represents a dividend yield of 1.07%. AstraZeneca’s payout ratio is 1.28%.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Net Margin
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.